Dr. Meritxell Bellet (Barcelona, 1967) graduated with a degree in Medicine and Surgery from the University of Barcelona (UB) in 1991, after which she completed her residency in Medical Oncology at Hospital de la Santa Creu i Sant Pau in Barcelona (1992-1995). She later worked as an assistant in different university hospitals (Hospital Sant Joan de Reus,  1996-1988; Vall d’Hebron Hospital, 1998-2000; Hospital Clínic, 2000-2001; Hospital del Mar, 2001-2005). Since 1998 her professional activity has been focused on breast cancer (BC). In 2005 she joined the Breast Cancer Unit of Vall d’Hebron Hospital in Barcelona as a senior oncologist. As a medical oncologist she has participated in clinical studies promoted by GEICAM and SOLTI (1996-2005), designed by herself (Phase II XELMAR study, 2000; SOFT-EST 2007) or within the pharmaceutical industry.

Since joining the Breast Cancer Unit of Vall d’Hebron Hospital (2005) and VHIO (2010), she has intensified her work in national and international clinical research, especially in relation to endocrine treatments and/or molecular therapies.  She has authored around thirty manuscripts, some published in high-impact journals such as the New England Journal of Medicine and the Journal of Clinical Oncology. In October 2016 she received her PhD. Her thesis, “Evaluation of the hormonal profile in patients with early BC undergoing adjuvant hormone therapy”, was awarded the qualification of Outstanding Cum Laude and the 2016-2017 Extraordinary Award by the Autonomous University of Barcelona (UAB).

Since 2015 she has been an active member of the SOLTI Group Scientific Committee, and since 2019 she has been a member of this this cooperative group’s Board of Directors as well as its treasurer. In the last five years she has been very active in the clinical development of cyclin-dependent kinase (CDK4/6) inhibitors and of new hormonal therapies (selective estrogen receptor degraders, anti-progestagens, and selective androgen receptor modulators) for luminal breast cancer. She is currently carrying out several projects at VHIO focused on prognostic reassessment of lobular cancer, on the determination of REbeta as a possible therapeutic target in triple-negative breast cancer, and on the development of ultrasensitive methods for accurate determination of estradiol in premenopausal patients with breast cancer subjected to ovarian function suppression and aromatase inhibitors. Finally, she is an active member of the Biovigilance Commission for Organ Transplants in Catalonia.